Uppsala, Sweden 2018-03-20
Biovica has received an order for the company's DiviTum® product from a global diagnostic and contract research company (CRO company). DiviTum will be used during the development of a new targeted drug against cancer to study the effectiveness of the treatment.
The value of the order is approximately 100 000 USD.
"New and more effective cancer treatment are important in order to improve patient outcome. At the same time, it’s expensive to develop new cancer drugs. With DiviTum, we aim to provide value both during development of new cancer drugs and during monitoring of treatment, for best possible patient outcome. ", says Anders Rylander, CEO Biovica.